Valuation : Norda ASA

Market Cap 51Cr 5.52Cr 4.75Cr 4.47Cr 4.08Cr 7.64Cr 521.07Cr 7.66Cr 53Cr 20Cr 267.34Cr 21Cr 20Cr 861.26Cr P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 26Cr 2.84Cr 2.45Cr 2.3Cr 2.1Cr 3.93Cr 268.42Cr 3.94Cr 27Cr 11Cr 137.72Cr 11Cr 10Cr 443.66Cr EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+0.12%
1 week+0.12%
Current month+0.12%
1 month-1.50%
3 months-1.50%
Current year-14.90%
1 week 85.1
Extreme 85.1
85.1
1 month 85
Extreme 85
85.1
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%+0.12%+5.06%+107.56% 4.7Cr
-0.97%-2.67%-1.58%+13.97% 4.89TCr
-0.40%+1.03%+418.57%+527.30% 4.5TCr
-1.42%+2.30%+42.67%+22.37% 4.41TCr
-1.22%-2.31%+4.82%+77.49% 4.07TCr
+0.53%-1.36%+16.87%+46.82% 3.35TCr
-0.21%+9.14% - - 1.78TCr
-0.35%-1.56%+21.42%+120.75% 1.65TCr
-1.62%-1.38%+11.92%+31.03% 1.47TCr
-1.65%-1.03%+75.93%+41.12% 1.38TCr
Average -0.72%+0.48%+66.19%+109.82% 2.75TCr
Weighted average by Cap. -0.79%+0.11%+89.33%+128.86%

Financials

2023 2024
Net sales 8.69Cr 93.48L 80.44L 75.68L 69.14L 1.29Cr 88Cr 1.3Cr 8.94Cr 3.47Cr 45Cr 3.51Cr 3.43Cr 145.88Cr 37Cr 4Cr 3.44Cr 3.24Cr 2.96Cr 5.53Cr 377.58Cr 5.55Cr 38Cr 15Cr 193.72Cr 15Cr 15Cr 624.09Cr
Net income 3.12Cr 33.52L 28.85L 27.14L 24.79L 46.38L 32Cr 46.51L 3.21Cr 1.24Cr 16Cr 1.26Cr 1.23Cr 52Cr 13Cr 1.35Cr 1.17Cr 1.1Cr 1Cr 1.87Cr 127.88Cr 1.88Cr 13Cr 5.03Cr 66Cr 5.09Cr 4.98Cr 211.38Cr
Net Debt -31Cr -3.35Cr -2.88Cr -2.71Cr -2.48Cr -4.63Cr -316.03Cr -4.64Cr -32Cr -12Cr -162.15Cr -13Cr -12Cr -522.36Cr -25Cr -2.68Cr -2.3Cr -2.17Cr -1.98Cr -3.7Cr -252.65Cr -3.71Cr -26Cr -9.93Cr -129.63Cr -10Cr -9.83Cr -417.6Cr
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. NORD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!